AstraZeneca has halted its £200m expansion in Cambridge, putting its full £650m UK investment plan on hold.
The project, expected to create 1,000 jobs, joins a scrapped £450m vaccine facility in Merseyside.
An AstraZeneca spokesperson confirmed the pause, citing ongoing reassessment of investment needs.
Meanwhile, the company pledged $50bn in US investments by 2030, funding new facilities and lab expansions across several states.
The announcement follows a challenging week for UK pharma, with Merck canceling a £1bn London research centre and laying off staff.
Sir John Bell warned that other major pharmaceutical companies may halt further investment in the UK.
Sanofi called for a clear Treasury plan, saying Britain is no longer competitive for drug development or sales.
Eli Lilly also paused its £279m London gateway lab project, deepening concerns for the sector.
Industry groups urge NHS pricing reforms, seeking a reduced clawback rate closer to European levels.
AstraZeneca Pauses £200m Cambridge Expansion Amid UK Pharma Setbacks
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment
© 2025 Health And Care Mag. All Rights Reserved.